{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:25:06Z","timestamp":1791869106533,"version":"4.3.4"},"reference-count":50,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"34","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,12,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> A phase II trial was conducted to determine if high-dose radiation with concurrent hepatic arterial floxuridine would improve survival in patients with unresectable intrahepatic malignancies. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Three-dimensional conformal high-dose radiation therapy was delivered concurrently with hepatic arterial floxuridine in 128 patients. The radiation dose was based on a normal-tissue complication probability model and subjected the patient to an estimated maximum risk of radiation-induced liver disease of 10% to 15%. The study design provided more than 80% power to detect a two-fold increase in median survival compared with historical controls at a 5% significance level. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> The median radiation dose delivered was 60.75 Gy (1.5-Gy fractions bid). At a median follow-up time of 16 months (26 months in patients who were alive) the median survival was 15.8 months (95% CI, 12.6 to 18.3 months), significantly longer than in the historical control. The actuarial 3-year survival was 17%. The total dose was the only significant predictor of survival. Primary hepatobiliary tumors had a significantly greater tendency to remain confined to the liver than did colorectal cancer metastases. Overall toxicity was acceptable, with 27 patients (21%) and 11 patients (9%) developing grade 3 and 4 toxicity, respectively, and one treatment-related death. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> The results suggest that, compared with historical controls, high-dose focal liver irradiation with hepatic artery floxuridine prolongs survival in patients with unresectable chemotherapy-refractory metastatic colorectal cancer and primary hepatobiliary tumors. This provides a rationale for intensification of local therapy for unresectable hepatobiliary cancers and integration of this regimen with newer systemic therapy for patients with colorectal cancer. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.01.5354","type":"journal-article","created":{"date-parts":[[2005,11,28]],"date-time":"2005-11-28T23:52:33Z","timestamp":1133221953000},"page":"8739-8747","source":"Crossref","is-referenced-by-count":287,"title":["Phase II Trial of High-Dose Conformal Radiation Therapy With Concurrent Hepatic Artery Floxuridine for Unresectable Intrahepatic Malignancies"],"prefix":"10.1200","volume":"23","author":[{"given":"Edgar","family":"Ben-Josef","sequence":"first","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Hematology Oncology, and Department of Surgery, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Normolle","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Hematology Oncology, and Department of Surgery, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Ensminger","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Hematology Oncology, and Department of Surgery, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Walker","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Hematology Oncology, and Department of Surgery, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tatro","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Hematology Oncology, and Department of Surgery, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall K.","family":"Ten Haken","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Hematology Oncology, and Department of Surgery, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Knol","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Hematology Oncology, and Department of Surgery, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Dawson","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Hematology Oncology, and Department of Surgery, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Pan","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Hematology Oncology, and Department of Surgery, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Hematology Oncology, and Department of Surgery, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01527-X"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14964-1"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505113321903"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80187-6"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000128305.90650.71"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1323"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02846-8"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.11.2210"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(89)90972-3"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01815-6"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Lindstrom M: Penalized estimation of free-knot splines. J Comput Graph Stat 8:333,1999-352,","DOI":"10.1080\/10618600.1999.10474817"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00286.x"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008285123736"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36824"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2217::AID-CNCR6>3.0.CO;2-M"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10607"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1097\/01.RVI.0000123319.20705.92"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10166-6"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20753"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh351"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602208"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1159\/000011961"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Colleoni M, Di Bartolomeo M, Di Leo A, et al: Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. Eur J Cancer 31A:2426,1995-2427,","DOI":"10.1016\/0959-8049(95)00347-9"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200008000-00023"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2311"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20368"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh172"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1023\/B:DRUG.0000011797.09549.53"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.20.4089"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008352123009"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016209901417"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00214-3"},{"key":"R35","unstructured":"Kubicka S, Rudolph KL, Tietze MK, et al: Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48:783,2001-789,"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.722"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Park HC, Seong J, Han KH, et al: Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 54:150,2002-155,","DOI":"10.1016\/S0360-3016(02)02864-X"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)00462-4"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200302000-00018"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00434-6"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.164"},{"key":"R42","unstructured":"Saltz LB, Ahmad SA, Vauthey J: Colorectal cancer: Management of advanced disease, in Kelsen DP, Daly JM, Kern SE, (eds): Gastrointestinal Oncology: Principles and Practice.  Philadelphia, PA, Lippincott Williams & Wilkins, pp 825,2002-852"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)02309-5"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03085-2"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf259"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.113"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19961015)78:8<1639::AID-CNCR1>3.0.CO;2-9"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.5.252"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912303412702"},{"key":"R50","unstructured":"Kemeny NE, Niedzwiecki D, Hollis DR: Hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer: A CALGB randomized trial of efficacy, quality of life (QOL), cost effectiveness, and molecular markers. Proc Am Soc Clin Oncol 22:252,2003,  (abstr 1010)"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(96)00528-7"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(04)01165-4"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.01.5354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:44:21Z","timestamp":1653511461000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.01.5354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,1]]},"references-count":50,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2005,12,1]]}},"alternative-id":["10.1200\/JCO.2005.01.5354"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.01.5354","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,1]]}}}